Physician profile
John Meier
NPI 1629299680
$9,800.25
in general payments reported to CMS, 2019-2025
60 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,535 · 2020: $405 · 2021: $643 · 2022: $1,377 · 2023: $2,383 · 2024: $1,804 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,839.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,500.28 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,479.42 | 2021-2025 | |
| Lilly USA, LLC | $934.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $927.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $527.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $430.12 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.63 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $346.72 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.25 | 2019-2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $252.97 | 2022-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $226.80 | 2021-2025 | |
| Bausch Health US, LLC | $188.70 | 2019-2024 | Aplenzin, Wellbutrin |
| Amgen INC. | $173.79 | 2019-2024 | Otezla, Repatha, Prolia |
| Supernus Pharmaceuticals, INC. | $162.96 | 2022 | |
| Axsome Therapeutics, INC. | $154.40 | 2024-2025 | Auvelity, Symbravo |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $121.85 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $101.29 | 2022 | |
| Merck Sharp & Dohme LLC | $99.72 | 2020-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Viiv Healthcare Company | $98.25 | 2024-2025 | Apretude |
| Novartis Pharmaceuticals Corporation | $89.87 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.52 | 2024-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $86.89 | 2019 | |
| Cequr Corporation | $84.86 | 2022-2024 | Cequr Simplicity |
| Sanofi Pasteur INC. | $84.80 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $83.64 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $80.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $61.64 | 2019-2021 | |
| Allergan, INC. | $53.57 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $43.79 | 2023-2024 | Gemtesa |
| Abiomed | $40.43 | 2024-2025 | Impella |
| Si-Bone, INC. | $38.32 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $38.21 | 2023-2024 | Evkeeza |
| Biohaven Pharmaceuticals, INC. | $32.47 | 2021 | |
| Edwards Lifesciences Corporation | $31.85 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mannkind Corporation | $29.02 | 2020 | |
| Lundbeck LLC | $25.59 | 2024 | Rexulti |
| Cranial Technologies, INC | $25.25 | 2019 | |
| Boston Scientific Corporation | $24.57 | 2022 | |
| Masimo Corporation | $23.39 | 2023 | Patient Safetynet System |
| Actelion Pharmaceuticals US, INC. | $21.88 | 2024 | Opsumit, Uptravi |
| Adlon Therapeutics L.P. | $19.17 | 2020 | |
| Medtronic, INC. | $18.94 | 2025 | Inceptiv |
| Ibsa Pharma INC. | $18.43 | 2021 | |
| Insightec,INC | $18.40 | 2025 | Exablate |
| Astellas Pharma US INC | $17.95 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $17.93 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $17.70 | 2019 | |
| Grifols USA, LLC | $17.32 | 2019 | |
| Phadia US INC. | $16.70 | 2025 | Immunocap |
| Dexcom, INC. | $16.66 | 2024 | Dexcom G6 Transmitter |
| Shire North American Group INC | $16.25 | 2019 | |
| Dynavax Technologies Corporation | $16.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.02 | 2021 | |
| Seqirus USA INC | $15.52 | 2025 | Fluad, Flucelvax |
| Echosens North America, INC. | $14.91 | 2025 | Fibroscan |
| E.R. Squibb & Sons, L.L.C. | $14.43 | 2021 | |
| Eisai INC. | $14.21 | 2021 | |
| Neos Therapeutics, LP | $14.07 | 2024 | Adzenys Xr-Odt |
| Genentech USA, INC. | $13.71 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.